Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:CLNN NASDAQ:PMCB NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.08-0.5%$0.25$0.08▼$1.35$21.28M2.1814.17 million shs83.23 million shsCLNNClene$3.49-1.4%$3.82$2.28▼$6.96$29.27M0.5555,384 shs362,287 shsPMCBNuvilex$1.00-2.0%$1.05$0.95▼$2.42$7M-0.2923,422 shs6,227 shsRNTXRein Therapeutics$1.11-4.7%$1.62$1.05▼$4.40$26.85M1.3146,174 shs24,881 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-0.50%-76.97%-67.04%-72.05%-93.99%CLNNClene-1.41%-4.38%-11.65%+17.11%-23.30%PMCBNuvilex-1.96%+4.71%-11.50%-17.36%-48.98%RNTXRein Therapeutics-4.72%-23.97%-27.92%-39.01%+110,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.4826 of 5 stars4.04.00.00.01.30.80.0CLNNClene3.4949 of 5 stars3.65.00.00.02.72.50.6PMCBNuvilex1.4822 of 5 stars0.05.00.00.00.60.81.9RNTXRein TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.00Hold$1.351,591.70% UpsideCLNNClene 3.17Buy$40.001,046.13% UpsidePMCBNuvilex 0.00N/AN/AN/ARNTXRein Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PMCB, ADAP, CLNN, and RNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/29/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/18/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.006/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.006/26/2025ADAPAdaptimmune TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$1.50 ➝ $0.505/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.465/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.12N/AN/A$0.05 per share1.60CLNNClene$340K84.89N/AN/A($1.06) per share-3.29PMCBNuvilexN/AN/AN/AN/A$3.27 per shareN/ARNTXRein TherapeuticsN/AN/A$0.43 per share2.60$0.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)CLNNClene-$39.40M-$4.04N/AN/AN/A-8,306.00%N/A-105.11%8/6/2025 (Estimated)PMCBNuvilex$330K$0.741.35∞N/AN/A0.51%0.35%8/12/2025 (Estimated)RNTXRein Therapeutics-$62.88M-$2.86N/AN/AN/AN/A-86.07%-31.11%N/ALatest PMCB, ADAP, CLNN, and RNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ADAPAdaptimmune Therapeutics-$0.11N/AN/AN/A$11.04 millionN/A8/6/2025Q2 2025CLNNClene-$0.49N/AN/AN/A$0.06 millionN/A5/15/2025Q1 2025RNTXRein Therapeutics-$0.21-$0.25-$0.04-$0.25N/AN/A5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics4.242.021.79CLNNCleneN/A1.361.36PMCBNuvilexN/A14.2114.21RNTXRein TherapeuticsN/A1.391.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%CLNNClene23.28%PMCBNuvilex34.24%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%CLNNClene35.30%PMCBNuvilex10.20%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million231.28 millionOptionableCLNNClene1008.27 million5.35 millionOptionablePMCBNuvilex46.86 million6.16 millionOptionableRNTXRein Therapeutics923.05 million21.02 millionN/APMCB, ADAP, CLNN, and RNTX HeadlinesRecent News About These CompaniesRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingJuly 30 at 4:59 PM | finance.yahoo.comRNTX - Rein Therapeutics Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMRein Therapeutics Announces Adjournment of Annual Meeting of StockholdersJune 24, 2025 | prnewswire.comUS FDA puts on hold Rein Therapeutics' lung disease drug trialJune 12, 2025 | reuters.comRNTX Rein Therapeutics Inc.June 1, 2025 | seekingalpha.comRein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | finanznachrichten.deRein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | prnewswire.comRein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International ConferenceMay 19, 2025 | prnewswire.comRein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deRein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | prnewswire.comRein Therapeutics begins trial for idiopathic pulmonary fibrosis treatmentMay 13, 2025 | msn.comRein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | finanznachrichten.deRein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | prnewswire.comRein Therapeutics to integrate Qureight’s platform in trial of IPF treatmentMay 2, 2025 | msn.comRein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPFMay 1, 2025 | prnewswire.comRein Therapeutics to Present at The Citizens Life Sciences Conference 2025April 30, 2025 | prnewswire.comRein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International ConferenceApril 28, 2025 | prnewswire.comRein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory DiseasesApril 23, 2025 | prnewswire.comRein Therapeutics reports IPF and PASC-F treatment progressApril 17, 2025 | uk.investing.comRein Therapeutics’ LTI-2355 peptide shows therapuetic potential in studyApril 16, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCB, ADAP, CLNN, and RNTX Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.08 0.00 (-0.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.08 0.00 (-0.38%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Clene NASDAQ:CLNN$3.49 -0.05 (-1.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.48 -0.01 (-0.14%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Nuvilex NASDAQ:PMCB$1.00 -0.02 (-1.96%) Closing price 08/1/2025 03:57 PM EasternExtended Trading$0.96 -0.04 (-3.80%) As of 08/1/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Rein Therapeutics NASDAQ:RNTX$1.11 -0.06 (-4.72%) As of 08/1/2025 03:59 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
